Most Likely Diagnosis: Primary Sjögren's Syndrome
The most likely diagnosis is primary Sjögren's syndrome (pSS), specifically a clinically distinct subset characterized by anticentromere antibody positivity. While anticentromere antibodies are classically associated with limited cutaneous systemic sclerosis (lcSSc), their presence in patients with sicca symptoms without Raynaud's phenomenon or fingertip ulcers strongly suggests a unique pSS phenotype rather than scleroderma.
Diagnostic Reasoning
Why Sjögren's Syndrome is Most Likely
The presence of sicca symptoms (dry eyes and mouth) is the cardinal feature pointing toward Sjögren's syndrome. A high degree of suspicion for Sjögren's syndrome is appropriate in patients who have clinically significant dry eye and dry mouth symptoms 1. The 2024 Dry Eye Syndrome guidelines emphasize that approximately 10% of patients with clinically significant dry eye have underlying Sjögren's syndrome 1.
The Anticentromere Antibody Paradox
The anticentromere antibody positivity creates diagnostic complexity, but research evidence clarifies this:
Anticentromere antibodies (ACA) can occur in primary Sjögren's syndrome and may define a clinically distinct subset 2. A 2010 study specifically identified pSS patients with ACA as having unique clinical features including sicca symptoms, arthralgias, and increased risk of extraglandular manifestations 2.
A 2023 study found that 57% of seronegative sicca patients (those without anti-Ro/SSA or anti-La/SSB) had scleroderma-specific autoantibodies, with CENP-B (anticentromere) being among the most common 3. This demonstrates that anticentromere antibodies can appear in sicca syndromes independent of classic scleroderma features.
Importantly, a 1992 study noted that 76% of anticentromere-positive patients had sicca syndrome, and this occurred with "quasi-absence of anti-SSA and anti-SSB antibodies," suggesting independence between sicca syndrome and sclerodermal manifestations 4.
Why NOT Systemic Sclerosis
The absence of Raynaud's phenomenon and fingertip ulcers argues strongly against systemic sclerosis as the primary diagnosis:
- According to the 2023 systemic sclerosis guidelines, 93% of anticentromere-positive patients have Raynaud's phenomenon, and 90% have complete or incomplete CREST syndrome features 4.
- The 2023 SSc guidelines note that anticentromere antibodies are associated with lcSSc, which typically presents with Raynaud's phenomenon as an early and nearly universal feature 5.
- Your patient lacks these hallmark scleroderma features, making primary SSc unlikely despite the antibody profile.
The Antichromatin and Antihistone Antibodies
The presence of antichromatin and antihistone antibodies further supports an autoimmune sicca syndrome:
- These antibodies are associated with various systemic autoimmune diseases including SLE and drug-induced lupus 6, but can also appear in overlap syndromes.
- Their presence alongside sicca symptoms and anticentromere antibodies suggests a complex autoimmune phenotype consistent with pSS rather than isolated scleroderma.
Recommended Diagnostic Workup
For patients suspected of having Sjögren's syndrome, serological examination should include:
- Anti-Sjögren syndrome A antibody (SSA or anti-Ro)
- Anti-Sjögren syndrome B antibody (SSB or anti-La)
- Rheumatoid factor
- Antinuclear antibody 1
Additional testing should include:
- Point-of-care biomarkers (salivary protein 1, carbonic anhydrase 6, parotid secretory protein) if available 1
- Schirmer test and tear break-up time for objective dry eye assessment
- Minor salivary gland biopsy if diagnosis remains uncertain 7
Clinical Implications and Monitoring
This anticentromere-positive pSS subset carries important prognostic implications:
- Increased risk of extraglandular systemic manifestations 2
- Potential increased risk of lymphoma (reported in the ACA-positive pSS cohort) 2
- Possible development of pulmonary complications including pulmonary hypertension and interstitial lung disease 3
Recommended screening per systemic sclerosis guidelines (applicable given antibody overlap):
- Baseline chest radiograph or high-resolution CT if pulmonary symptoms develop 8
- Pulmonary function tests including DLCO 5
- Echocardiography if dyspnea or concern for pulmonary hypertension develops 8
- Regular blood pressure monitoring (though scleroderma renal crisis risk is low without other SSc features) 5
Management Approach
Co-management with rheumatology is essential 1, 7. Patients with Sjögren's syndrome should be managed by rheumatology owing to possible comorbid systemic conditions and the need for immunomodulatory therapy if systemic features develop.
Initial symptomatic treatment:
- Artificial tears and topical therapies for dry eyes 1, 7
- Saliva substitutes and oral muscarinic agonists (pilocarpine or cevimeline) for dry mouth 1, 7
- Hydroxychloroquine may be considered for systemic symptoms 7
Common Pitfalls to Avoid
- Do not dismiss Sjögren's syndrome solely because anticentromere antibodies are present - this represents a recognized clinical subset
- Do not diagnose systemic sclerosis without Raynaud's phenomenon - it is present in >90% of anticentromere-positive SSc cases
- Do not assume all sicca patients are anti-Ro/SSA or anti-La/SSB positive - seronegative Sjögren's exists and may have alternative antibody profiles 3
- Do not neglect long-term monitoring - this subset may have increased risk of lymphoproliferative disorders and systemic complications 2